Literature DB >> 7699044

Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1.

R W Shafer1, E Aguiniga, T C Merigan.   

Abstract

Among 75 consecutive human immunodeficiency virus type 1 (HIV-1)-infected patients with moderate and advanced immunosuppression, those harboring syncytium-inducing (SI) HIV-1 had a lower CD(4+)-cell count (145 versus 278 cells per microliter, P < 0.001) and 10-fold-higher virus titers than patients with non-SI HIV-1 (398 versus 39 infectious units per 10(6) CD4+ lymphocytes; P < 0.001). In patients with SI virus, the mean titer of SI virus, determined with a quantitative MT-2 cell assay, was 135 SI infectious units per 10(6) CD4+ lymphocytes. Virus titer correlated inversely with CD(4+)-cell count in patients with SI (r = -0.67) but not non-SI (r = -0.29) virus.

Entities:  

Mesh:

Year:  1995        PMID: 7699044      PMCID: PMC227911          DOI: 10.1128/jcm.33.1.212-214.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells.

Authors:  R Wood; H Dong; D A Katzenstein; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-03

Review 2.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

3.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

Authors:  D D Ho; T Moudgil; M Alam
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

4.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Plasma viremia in human immunodeficiency virus infection.

Authors:  R W Coombs; A C Collier; J P Allain; B Nikora; M Leuther; G F Gjerset; L Corey
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

6.  The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.

Authors:  S M Schnittman; M C Psallidopoulos; H C Lane; L Thompson; M Baseler; F Massari; C H Fox; N P Salzman; A S Fauci
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

7.  Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS.

Authors:  P Gupta; L Kingsley; J Armstrong; M Ding; M Cottrill; C Rinaldo
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

8.  Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.

Authors:  R I Connor; H Mohri; Y Cao; D D Ho
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

10.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.